Navigation Links
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
Date:5/6/2008

BERKELEY HEIGHTS, N.J., May 6 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has received notification from the NASDAQ Listing Qualifications Panel that the Company had failed to demonstrate its ability to sustain compliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Capital Markets. The Panel has also determined that de-listing from The NASDAQ Capital Markets will occur at the market open effective Tuesday, May 6, 2008.

In view of this event, the Company intends to move the trading of its common stock from The NASDAQ Capital Markets to the Over-the-Counter Bulletin Board (OTCBB) maintained by FINRA (formerly, the NASD). The Company has been advised that a "market maker" has filed the requisite Form 211 application to quote the Company's securities on the OTCBB with the Financial Industry Regulatory Authority (FINRA). The Company is not aware of any deficiencies in that application, and it is the Company's expectation that FINRA will promptly clear the market maker's application, and that the Company's securities will be eligible for trading on the OTCBB.

The Company plans to make a further announcement on the timing of the transfer to the OTCBB following formal receipt of the FINRA clearance notice. If cleared, quotations for the Company's common stock on the OTCBB will continue under the symbol GNTA. Until such formal notice is received, the Company's common stock will be traded under the symbol GNTA.PK.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Elizabeth Brown Joins Argenta TEC
2. Syngenta To Build Major Global Biotech Research Center in Beijing, China
3. Genta Restructures Operations to Focus on Priority Initiatives
4. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
5. Auditors for Genta Incorporated Express Going Concern Qualification
6. Genta Announces Senior Management Changes
7. Genta Announces Common Stock Offering of Approximately $3.1 Million
8. Genta Incorporated to Present at the BIO CEO & Investor Conference
9. Genta Receives Notice of Non-Compliance With NASDAQ Rule
10. Genta Receives NASDAQ Non-Compliance Notice
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... law H.R. 83, the Omnibus and Continuing Resolution Appropriations ... hydrocephalus a condition eligible to receive funding through the ... Department of Defense (DoD). The Hydrocephalus Association (HA), working ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... , RICHMOND, Calif. , ... announced today that Edward Lanphier , Sangamo,s president and CEO, will ... and an overview of the company,s business strategy at 9:00 am ... Annual BIO CEO & Investor Conference which will be held in ...
... , , SAN FRANCISCO , ... MERR ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... million shares of common stock, and warrants to purchase 4.2 million ... today. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working ...
... , TSX Exchange Symbol: RVX , CALGARY, Feb. 1 ... announced today that the Board of Directors has elected ... of the Bayer HealthCare Executive Committee, to the Board effective ... in 2004 as Chairman of the Bayer HealthCare Executive Committee ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 2Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 3Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 4
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Yale University have discovered that a specialized receptor, normally ... throughout the body, sensing small molecules created by microbes ... by increasing blood pressure. The finding suggests that gut ... system for maintaining a stable blood pressure. A ...
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... from Michigan State University have successfully engineered a plant with ... as well as lead to improved animal feeds. The ... Cell , the journal of the American Society of Plant ... in oil production to engineer a plant that stores lipids ...
Cached Biology News:Blood vessels 'sniff' gut microbes to regulate blood pressure 2Blood vessels 'sniff' gut microbes to regulate blood pressure 3Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2'Fat worms' inch scientists toward better biofuel production 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
...
... The OneSTrEP Protein Interaction Kit ... single step method to isolate intact ... require tedious optimization or multiple purification ... the highly selective StrepTactin Superflow Column ...
Biology Products: